Launch Conditionality: What’s at stake?
The increasing importance of Real World Evidence (RWE) and the need for a multi-stakeholder approach
What is Needed to Reinforce Biopharmaceutical Innovation in Europe?
The European Health Data Space (EHDS): How will it impact health technology companies operating in or about to enter the EU?
From the EUCOPE Blog archives
GUEST: What’s on the horizon for life sciences and health care?
June 30, 2022
Five Priorities for a Successful EU HTA Procedure
April 27, 2022
HERA: closer coordination in the EU against COVID-19
February 26, 2021
Is it Time for a new Health Paradigm in the EU?
November 20, 2020
Harnessing Europe’s untapped potential: small and medium pharma
June 2, 2020
To the archives
